STANDARDIZATION of terminology for drugs and scientific substances appears to be a highly desirable goal. Exchange of information through publication and individual communication would be far less subject to misinterpretation if nomenclature were precise and unchanged. Furthermore, increase in world travel makes it more necessary than ever that patients, physicians, and pharmacists be able severally to request and comply with requests for drugs without worry about differences in names. International health co-operation and regional health program would obviously benefit from simplification of terminology.
The situation has recently been reviewed by P. Blanc, Secretary of the World Health Organization Expert Committee on the International Pharmacopoeia, before the International Pharmaceutical Federation. His paper has been summarized in the Chronicle of the World Health Organization, for November 1952, volume 6, page 322, from which the following extracts are taken:
"At first sight it might seem that, for the numerous drugs which are chemical compounds, the chemical names could be used; but the latter are often so complicated that manufacturers and sales agents spontaneously adopt simpler and shorter names. Obviously `riboflavine' sounds better and is more easily remembered than 6:7-dimethyl-9-(D-1'-ribityl)izo-alloxazine. But, unfortunately, the same substance is known elsewhere by the name of `lactoflavine' or `vitamin B2'. Another example may be cited, namely that of the methadone hydrochloride of the Pharmacopoea Internationalis (6-dimethylamino-4,4-diphenyl-3-heptanone), which is known in different countries under the following names: amidone, miadone, diadone, diaminon, mephenon, symoron, etc.
Global Collaborative Team Performance for the Revision of the International Classification of Diseases: A Case Study of the World Health Organization Field Studies Coordination Group
